Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy

CMAJ. Canadian Medical Association Journal

Volumn 182, Issue 17, 2010, Pages 1857-1862

  Kang, Xinmei ^a   Zhang, Qingyuan ^a   Wang, Shuhuai ^a   Huang, Xu ^a   Jin, Shi ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; ISOFLAVONE DERIVATIVE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CONFIDENCE INTERVAL; DIETARY INTAKE; FEMALE; FOOD FREQUENCY QUESTIONNAIRE; HAZARD RATIO; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREMENOPAUSE;

EID: 78649611550     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.091298     Document Type: Article

References (25)

1. Tham DM, Gardner CD, Haskell WL. Clinical review 97: Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab 1998;83:2223-35.
2. Setchell KD. Soy isoflavones - benefits and risks from nature's selective estrogen receptor modulators (SERMs). J Am Coll Nutr 2001;20 Suppl:354S-62S.
3. Atmaca A, Kleerekoper M, Bayraktar M, et al. Soy isoflavones in the management of postmenopausal osteoporosis. Menopause 2008;15:748-57.
4. Cassidy A, Hooper L. Phytoestrogens and cardiovascular disease. J Br Menopause Soc 2006;12:49-56.
5. Ingle JN. Current status of adjuvant endocrine therapy for breast cancer. Clin Cancer Res 2001;7 Suppl:4392s-6s.
6. Colozza M, Califano R, Minenza E, et al. Aromatase inhibitors: a new reality for the adjuvant endocrine treatment of early-stage breast cancer in postmenopausal women. Mini Rev Med Chem 2008;8:564-74.
7. Ju YH, Doerge DR, Allred KF, et al. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 2002;62:2474-7.
8. Liu B, Edgerton S, Yang X, et al. Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. Cancer Res 2005;65:879-86. (Pubitemid 40216447)
9. Constantinou AI, Lantvit D, Hawthorne M, et al. Chemopreventive effects of soy protein and purified soy isoflavones on DMBA-induced mammary tumors in female Sprague-Dawley rats. Nutr Cancer 2001;41:75-81.
10. Dai Q, Shu XO, Jin F, et al. Population-based case-control study of soyfood intake and breast cancer risk in Shanghai. Br J Cancer 2001;85:372-8.
11. Yang YX, Wang GY, Chang PX. Isoflavone content of foods. In: China food composition. Beijing (China): University Medical Publishing House; 2002. p. 331-4.
12. Hsieh FY, Lavori PW. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials 2000;21:552-60.
13. Hess KR. Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions. Stat Med 1994;13:1045-62.
14. Messina M, Nagata C, Wu AH. Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer 2006;55:1-12.
15. Shu XO, Jin F, Dai Q, et al. Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. Cancer Epidemiol Biomarkers Prev 2001; 10: 483-8. (Pubitemid 32701634)
16. Wu AH, Wan P, Hankin J, et al. Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis 2002;23:1491-6. (Pubitemid 35012429)
17. Messina MJ, Wood CE. Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary. Nutr J 2008;7:17.
18. Boyapati SM, Shu XO, Ruan ZX, et al. Soyfood intake and breast cancer survival: a followup of the Shanghai Breast Cancer Study. Breast Cancer Res Treat 2005;92:11-7.
19. Guha N, Kwan ML, Quesenberry CP Jr, et al. Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. Breast Cancer Res Treat 2009;118:395-405.
20. Nakata T, Takashima S, Shiotsu Y, et al. Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients. J Steroid Biochem Mol Biol 2003;86:455-60.
21. Pasqualini JR, Chetrite GS. Recent insight on the control of enzymes involved in oestrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol 2005;93:221-36.
22. Lacey M, Bohday J, Fonseka SM, et al. Dose-response effects of phytoestrogens on the activity and expression of 3β-hydroxysteroid dehydrogenase and aromatase in human granulosa-luteal cells. J Steroid Biochem Mol Biol 2005;96:279-86.
23. Brooks JD, Thompson LU. Mammalian lignans and genistein decrease the activities of aromatase and 17β-hydroxysteroid dehydrogenase in MCF-7 cells. J Steroid Biochem Mol Biol 2005;94:461-7.
24. Touillaud MS, Thiébaut AC, Fournier A, et al. Dietary lignan intake and postmenopausal breast cancer risk by estrogen and progesterone receptor status. J Natl Cancer Inst 2007;99:475-86. (Pubitemid 47078736)
25. Gaudet MM, Britton JA, Kabat GC, et al. Fruits, vegetables, and micronutrients in relation to breast cancer modified by menopause and hormone receptor status. Cancer Epidemiol Biomarkers Prev 2004;13:1485-94.